Moreover, Hes1 seems to be a favorite target but not sufficient itself to target GBM efficaciously; therefore we suggested that any potential pharmacological intervention should provide for the use of anti-Stat3/5 drugs either alone or in combination regimen [2]. This evidence concerns the gene STAT3 and glioblastoma.